2 results
Approved WMOCompleted
To measure in vivo biodistribution of 89Zirconium labeled GSK2849330 and characterize its dose receptor occupancy relationship in subjects with advanced HER3 positive solid malignancies.
Approved WMOPending
To find a suitable treatment option for the 25% of HS patients who are therapy-resistant. Additionally, we expect a faster healing time of the wounds, meaning that even if patients respond to current treatment, HBOT may improve their quality of lifeā¦